Table 3.
Response by variable of interest for patients treated with ipilimumab + nivolumab
| Variable | Total N | Response N, % | No response N, % | P value |
|---|---|---|---|---|
| Age | ||||
| ≤ 60 years | 30 | 18 (60) | 12 (40) | |
| >60 years | 27 | 18 (67) | 9 (33) | |
| Sex | ||||
| Male | 37 | 25 (68) | 12 (32) | |
| Female | 20 | 11 (55) | 9 (45) | |
| Site of metastases | * | |||
| Brain | 10 | 6 (60) | 4 (40) | 0.84 |
| Liver | 13 | 8 (62) | 5 (38) | 0.89 |
| Lung | 23 | 15 (65) | 8 (35) | 0.79 |
| Bone | 12 | 10 (83) | 2 (17) | 0.10 |
| Skin/soft tissue | 24 | 16 (67) | 8 (33) | 0.64 |
| Lymph node | 35 | 25 (71) | 10 (29) | 0.10 |
| Other visceral | 12 | 9 (74) | 3 (25) | 0.34 |
| Number of metastases | ||||
| 1–3 | 15 | 6 (40) | 9 (60) | 0.07 |
| 4–10 | 25 | 19 (76) | 6 (24) | |
| ≥11 | 17 | 11 (65) | 6 (35) | |
| Largest tumor diameter | ||||
| <2cm | 11 | 6 (55) | 5 (45) | 0.56 |
| 2–5cm | 29 | 17 (59) | 12 (41) | |
| 5–8cm | 10 | 8 (80) | 2 (20) | |
| >8cm | 7 | 5 (71) | 2 (29) | |
| AJCC stage | ||||
| IIIc/M1a | 16 | 9 (56) | 7 (44) | 0.39 |
| M1b | 10 | 5 (50) | 5 (50) | |
| M1c | 31 | 22 (71) | 9 (29) | |
| LDH | ||||
| ≤ULN | 30 | 20 (67) | 10 (33) | 0.48 |
| >ULN | 26 | 15 (58) | 11 (42) | |
AJCC, American Joint Committee for Cancer; LDH, lactate dehydrogenase; ULN, upper limit of normal